List of Excipients in Branded Drug DORZOLAMIDE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE	dorzolamide hydrochloride and timolol maleate	50383-261	HYDROXYETHYL CELLULOSE
Akorn	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE	dorzolamide hydrochloride and timolol maleate	50383-261	MANNITOL
Akorn	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE	dorzolamide hydrochloride and timolol maleate	50383-261	SODIUM CITRATE
Akorn	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE	dorzolamide hydrochloride and timolol maleate	50383-261	SODIUM HYDROXIDE
Akorn	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE	dorzolamide hydrochloride and timolol maleate	50383-261	WATER

Generic Drugs Containing DORZOLAMIDE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Indoco Remedies Limited	dorzolamide	14445-404	BENZALKONIUM CHLORIDE
Indoco Remedies Limited	dorzolamide	14445-404	HYDROXYETHYL CELLULOSE
Indoco Remedies Limited	dorzolamide	14445-404	MANNITOL
Indoco Remedies Limited	dorzolamide	14445-404	SODIUM CITRATE
Indoco Remedies Limited	dorzolamide	14445-404	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in DORZOLAMIDE HYDROCHLORIDE?

# Of NDCs	Excipient
16	BENZALKONIUM CHLORIDE
16	HYDROXYETHYL CELLULOSE
16	MANNITOL
4	SODIUM CITRATE
16	SODIUM HYDROXIDE

Dorzolamide Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Dorzolamide hydrochloride is an established ophthalmic carbonic anhydrase inhibitor with limited remaining originator exclusivity and broad generic availability. The principal commercial opportunities are no longer based on active-ingredient exclusivity. They are concentrated in preservative-free delivery, multidose packaging, ocular-surface tolerability, fixed-dose combinations, manufacturing efficiency, and differentiated regulatory positioning.

The reference product, Trusopt, is a 2% dorzolamide hydrochloride ophthalmic solution. Its core excipient system uses mannitol, hydroxyethyl cellulose, sodium citrate, benzalkonium chloride and purified water, with pH adjustment using sodium hydroxide or hydrochloric acid. The formulation is designed to maintain dorzolamide solubility, control pH, provide adequate ocular residence time and preserve the multidose container [1].

What is dorzolamide hydrochloride and how is it used?

Dorzolamide hydrochloride is a topical ophthalmic carbonic anhydrase inhibitor indicated to reduce elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It is administered as a 2% ophthalmic solution, generally one drop three times daily as monotherapy or twice daily when used with another topical glaucoma medicine [1].

Dorzolamide is also marketed in combination with timolol maleate as a fixed-dose ophthalmic solution under the Cosopt brand and generic equivalents. The combination is used when monotherapy is insufficient to control intraocular pressure [2].

Attribute	Dorzolamide hydrochloride
Therapeutic class	Ophthalmic carbonic anhydrase inhibitor
Reference brand	Trusopt
Combination brand	Cosopt
Typical strength	2% ophthalmic solution
Dosage form	Sterile topical eye drops
Main indication	Ocular hypertension and open-angle glaucoma
FDA reference approval	Trusopt approved in 1994
Combination approval	Cosopt approved in 1998
Biologic status	Not applicable
Current competitive basis	Formulation, packaging, tolerability, supply and price

Dorzolamide is a small molecule. Biosimilar competition is therefore irrelevant. Competitive products are generic drug products regulated through abbreviated new drug applications, or ANDAs, rather than biosimilar applications.

What excipients are used in dorzolamide hydrochloride ophthalmic products?

The standard dorzolamide excipient platform is an aqueous, buffered, viscosity-modified and preserved solution.

Excipient	Primary function	Commercial or technical consideration
Mannitol	Tonicity adjustment and bulking agent	Helps produce a physiologically acceptable formulation without relying on high sodium chloride levels
Hydroxyethyl cellulose	Viscosity modifier and residence-time enhancer	Supports drop retention and may reduce drainage from the ocular surface
Sodium citrate dihydrate	Buffer component and pH control	Helps stabilize the formulation near the target acidic pH
Benzalkonium chloride	Antimicrobial preservative	Enables multidose packaging but can create ocular-surface tolerability concerns
Sodium hydroxide or hydrochloric acid	Final pH adjustment	Used during manufacturing to achieve the specified pH
Purified water	Vehicle	Must meet ophthalmic water-quality and microbial-control requirements

The reference product has an acidic formulation, with a labeled pH of approximately 5.5 [1]. That pH supports product stability and solubility but may contribute to transient stinging after administration. Any reformulation that shifts pH toward physiological conditions must demonstrate chemical stability, preservative effectiveness, ocular tolerability and container compatibility.

Why hydroxyethyl cellulose matters

Hydroxyethyl cellulose is a practical excipient choice for dorzolamide because it increases viscosity without creating the high structural complexity associated with gels or suspensions. It can increase ocular residence time and reduce immediate tear drainage. The tradeoff is a possible increase in blurred vision, drop-string formation, microbial-control demands and manufacturing viscosity.

Alternative viscosity agents include hypromellose, polyvinyl alcohol, povidone, carbomers and hyaluronic-acid derivatives. Each creates a different regulatory and commercial profile:

• Hypromellose is familiar in ophthalmic products and can support a lower-cost generic formulation.
• Povidone can improve lubrication and surface wetting but may alter drop feel.
• Carbomer systems provide stronger residence-time effects but can create blur and rheology challenges.
• Hyaluronic acid can support ocular-surface positioning but may increase ingredient cost and regulatory differentiation requirements.
• Polyvinyl alcohol may offer a simpler manufacturing process but may not reproduce the same residence time as hydroxyethyl cellulose.

What preservative strategy is best for dorzolamide eye drops?

The strongest commercial opportunity is a preservative-free or low-exposure multidose product. Benzalkonium chloride is effective and familiar, but chronic exposure is associated with ocular-surface irritation and toxicity concerns, particularly in patients with long-term glaucoma treatment, dry eye, multiple topical medicines or compromised corneal surfaces [3].

Three strategies are commercially relevant.

Preserved multidose formulation

This is the lowest-cost and lowest-development-risk approach. The manufacturer retains benzalkonium chloride and uses a conventional multidose bottle.

Advantages include:

• Established excipient precedent
• Simple preservative-effectiveness testing
• Low packaging cost
• Familiar manufacturing process
• Straightforward generic substitution strategy

The weakness is limited differentiation. Price competition is likely to be intense unless the product has a supply advantage or a preferred payer position.

Preservative-free unit-dose product

A unit-dose vial eliminates the need for benzalkonium chloride. This approach may be attractive for patients with ocular-surface disease and for ophthalmologists seeking to reduce cumulative preservative exposure.

The principal disadvantages are higher packaging, filling and logistics costs. Unit-dose products also generate more material waste and require careful control of extractables, particulates, container closure integrity and dose uniformity.

Preservative-free multidose container

A preservative-free multidose system can offer the greatest commercial differentiation. It requires a validated dispensing package that prevents microbial ingress or uses a sterile barrier mechanism. Relevant technologies include one-way valves, airless systems, filtered venting and mechanically protected dispensing tips.

The commercial value is potentially higher than a standard generic, but the device becomes part of the product's regulatory and intellectual-property profile. The manufacturer must validate the assembled drug-device system, not only the liquid formulation.

What formulation patents protect dorzolamide hydrochloride products?

Dorzolamide's original product and formulation patent estate is historical rather than a major current barrier to entry. The active ingredient was developed by Merck, and the Trusopt product was approved in the 1990s. Core United States patent protection associated with dorzolamide and its ophthalmic use expired years ago, allowing multiple generic manufacturers to enter.

The commercial assessment should distinguish between three patent categories:

Patent category	Dorzolamide relevance	Current entry significance
Active ingredient and synthesis patents	Protect the original dorzolamide molecule or chemical process	Generally expired
Basic ophthalmic composition patents	Cover aqueous dorzolamide solutions and excipient combinations	Generally expired or no longer blocking routine generic entry
Device, preservative-free and differentiated formulation patents	May cover modern multidose systems, specific viscosity ranges or combination products	Potentially relevant for new entrants

Historical patent numbers associated with dorzolamide development and ophthalmic compositions include U.S. patents issued to Merck-related entities during the development period. Their terms were tied to filings from the 1980s and early 1990s and do not provide a current platform for blocking ordinary dorzolamide hydrochloride generic solutions. Current freedom-to-operate work should focus on later patents covering packaging, preservative-free delivery, manufacturing controls and specific combination formulations.

A product developer should not assume that an expired active-ingredient estate creates freedom to copy every commercial presentation. A proprietary pump, valve, vial geometry, coating, stabilizer system or combination-drug presentation may have separate protection.

When did dorzolamide hydrochloride lose exclusivity?

Trusopt's market exclusivity ended after the expiration of its original regulatory and patent protections. FDA approval occurred in 1994, and generic dorzolamide ophthalmic products subsequently entered the U.S. market through ANDA pathways.

Cosopt faced a separate exclusivity profile because it combines dorzolamide with timolol. The combination product required separate regulatory review and had separate listed patents and exclusivity considerations. Generic dorzolamide/timolol products have also entered the U.S. market.

Product	First FDA approval period	Generic pathway	Current status
Trusopt, dorzolamide 2%	1994	ANDA	Generic competition established
Cosopt, dorzolamide/timolol	1998	ANDA	Generic competition established
Preservative-free or device-differentiated presentations	Later development	NDA, 505(b)(2) or ANDA depending on changes	Product-specific review required

The Orange Book should be reviewed for the relevant reference-listed drug and any currently listed patents before launch. The existence of an Orange Book listing does not by itself establish that the patent blocks every formulation or that a Paragraph IV challenge will be necessary. The claim scope and expiration date must be assessed against the proposed product.

What is the Orange Book status of dorzolamide hydrochloride?

Dorzolamide ophthalmic solution is associated with an FDA reference-listed drug and generic ANDA products. The Orange Book is the controlling source for current patent listings, regulatory exclusivity and reference-product information [4].

For a new dorzolamide product, the regulatory route depends on the extent of formulation and device change:

• A conventional 2% solution that matches the reference product may be suitable for an ANDA.
• A formulation with materially different excipients may still qualify for an ANDA if equivalence and pharmaceutical sameness requirements are met.
• A preservative-free product may require a more complex ANDA justification or a 505(b)(2) application, depending on the formulation, container and clinical or labeling differences.
• A novel device or delivery system can create combination-product review requirements.

The principal regulatory risk is not the active ingredient. It is demonstrating equivalent drug release, dose delivery, sterility, preservative performance where applicable, container compatibility and product stability.

How many patents cover current dorzolamide products?

No single number is commercially meaningful without defining the product, jurisdiction, formulation and time of review. The historical estate for the basic molecule and conventional ophthalmic solution is substantially less important than any later patent covering a differentiated presentation.

A practical patent screen should include:

1. Current Orange Book-listed patents for the reference product.
2. U.S. and foreign patents on preservative-free multidose containers.
3. Patents on ophthalmic dropper valves and sterile dispensing systems.
4. Patents claiming specific viscosity, pH, buffer or tonicity ranges.
5. Patents covering dorzolamide/timolol fixed-dose combinations.
6. Manufacturing patents for sterile filtration, aseptic filling or low-particulate production.
7. Patent applications filed by excipient, packaging and ophthalmic-device suppliers.

The likely risk profile is low for a conventional preserved generic and higher for a device-led or preservative-free product.

Which companies compete in dorzolamide hydrochloride?

Competition includes the originator, generic pharmaceutical companies and ophthalmic contract manufacturers. Market participation changes by country and supply contract.

The major competitive groups are:

• Merck, associated with Trusopt and Cosopt.
• Large generic manufacturers with ophthalmic manufacturing capacity.
• Specialty ophthalmology companies with branded or differentiated products.
• Contract development and manufacturing organizations, or CDMOs, supplying sterile ophthalmic filling.
• Packaging suppliers offering preservative-free multidose systems.

The strongest competitive differentiators are product availability, wholesale acquisition cost, payer coverage, bottle performance, drop size, preservative exposure and manufacturing reliability. A low-cost conventional product competes primarily on price. A preservative-free product competes on tolerability, adherence and specialist prescribing.

What generic launch scenarios exist for dorzolamide hydrochloride?

Scenario 1: Standard preserved generic

A manufacturer uses the reference excipient architecture and a conventional multidose bottle. This is the fastest and least expensive route, but it faces intense price pressure and limited brand loyalty.

Scenario 2: Lower-cost formulation optimization

The manufacturer uses a comparable buffer and viscosity system while improving yield, reducing overfill, minimizing batch losses and optimizing container fill volume. The commercial benefit comes from cost of goods rather than premium pricing.

Scenario 3: Preservative-free unit-dose product

This product targets patients with ocular-surface sensitivity, high preservative burden or post-surgical treatment needs. It can command a higher net price but must absorb packaging and distribution costs.

Scenario 4: Preservative-free multidose product

This is the most differentiated option. The opportunity is strongest where physicians actively switch patients away from benzalkonium chloride. The main barriers are device qualification, microbial protection and potential patent exposure.

Scenario 5: Dorzolamide/timolol combination

The combination can improve adherence by reducing bottle count and administration frequency. It competes directly with generic Cosopt-equivalent products and may require a separate patent and regulatory assessment.

What excipient and manufacturing barriers affect commercial entry?

Sterile ophthalmic manufacturing is the primary operational barrier. The product must control bioburden, endotoxin, particulate matter, visible and subvisible particles, container closure integrity and fill-volume variability.

Key manufacturing issues include:

• Dorzolamide hydrochloride solubility at the target concentration and pH.
• Buffer capacity and pH drift during shelf life.
• Interaction between benzalkonium chloride and the container or closure.
• Adsorption of the active ingredient or preservative to packaging components.
• Viscosity-related filling accuracy.
• Filter compatibility and active-ingredient recovery.
• Drop size consistency across bottle orientation and remaining fill volume.
• Sterility assurance for unit-dose and multidose formats.
• Extractables and leachables from plastic containers and elastomeric components.

Hydroxyethyl cellulose can increase process complexity because viscosity affects filtration, mixing and filling. A lower-viscosity alternative may reduce manufacturing cost but could change ocular residence time and drop behavior.

How does dorzolamide compare with brinzolamide?

Dorzolamide and brinzolamide are topical carbonic anhydrase inhibitors, but their formulation profiles differ.

Factor	Dorzolamide hydrochloride	Brinzolamide
Typical product form	Aqueous solution	Ophthalmic suspension
Typical strength	2%	1%
Formulation burden	Solubility and pH control	Particle-size, suspension and redispersibility control
Preservative issue	Benzalkonium chloride in conventional products	Benzalkonium chloride in conventional products
Manufacturing complexity	Lower	Higher because of suspension control
Differentiation opportunity	Preservative-free and device-led	Suspension performance and tolerability
Generic manufacturing	Relatively accessible for sterile ophthalmic producers	More technically demanding

Dorzolamide is generally more attractive for a first ophthalmic generic or reformulation platform because it can be manufactured as a solution. Brinzolamide may offer stronger formulation differentiation but carries greater suspension-development risk.

What licensing deals and partnering opportunities exist?

The most credible partnering opportunities are formulation and manufacturing transactions rather than licenses to the dorzolamide molecule.

Potential deal structures include:

• Licensing a preservative-free multidose container.
• Acquiring rights to a validated ophthalmic device in selected territories.
• Contracting a CDMO for sterile filling and packaging.
• Co-developing a dorzolamide/timolol product with a specialty ophthalmology company.
• Licensing a regional dossier for markets with limited generic competition.
• Supplying a proprietary excipient or packaging component under a long-term agreement.

A platform deal can be more valuable than a single-product license if the same container system supports timolol, latanoprost, brimonidine, dorzolamide and combination products. The principal diligence points are device patent term, regulatory precedents, manufacturing capacity, extractables data, human-factors testing and supply continuity.

What patent litigation and Paragraph IV risks affect dorzolamide?

Conventional dorzolamide products have a mature generic market, so the principal Paragraph IV opportunity is limited to later patents covering differentiated formulations or devices. A generic applicant challenging an active Orange Book patent may file a Paragraph IV certification under the Hatch-Waxman Act [5].

For a standard preserved 2% solution, the most likely risk is commercial price erosion rather than prolonged patent litigation. For a preservative-free multidose product, litigation risk may shift from the active ingredient to the dispenser, container closure and formulation claims.

A launch strategy should evaluate:

• Whether the reference product has current Orange Book-listed patents.
• Whether the proposed formulation practices any later formulation patent.
• Whether the container is covered by third-party device claims.
• Whether a Paragraph IV filing creates a 30-month stay risk.
• Whether a settlement agreement restricts launch timing or product design.
• Whether the product can launch with a non-infringing package.

No biosimilar litigation pathway applies because dorzolamide is a chemically synthesized small molecule.

What is the revenue exposure and market opportunity?

Revenue exposure depends on whether the product is positioned as a commodity generic or as a differentiated ophthalmic product.

Positioning	Revenue profile	Main risk
Standard generic solution	High volume, low margin	Rapid price erosion
Hospital or institutional supply	Contract-driven, predictable volume	Tender pricing and supply penalties
Preservative-free unit dose	Higher price per treatment	Packaging cost and waste
Preservative-free multidose	Potential premium and specialist uptake	Device validation and patent risk
Dorzolamide/timolol combination	Adherence-based value proposition	Crowded generic competition
Regional specialty product	Potentially stronger margins	Smaller addressable market

The most defensible commercial strategy is a two-tier portfolio: a low-cost preserved generic for volume and a preservative-free product for specialist and ocular-surface segments. The same sterile manufacturing platform can support both products if the packaging and preservative controls are designed early.

Key Takeaways

• Dorzolamide hydrochloride is a mature generic ophthalmic product, not a molecule with meaningful remaining basic exclusivity.
• The standard excipient system consists of mannitol, hydroxyethyl cellulose, sodium citrate, benzalkonium chloride and water.
• Benzalkonium chloride is the central tolerability issue and the main opening for differentiated product development.
• Preservative-free multidose packaging offers the strongest premium opportunity but creates device, microbiology, regulatory and patent risks.
• A conventional preserved generic is easier to launch but is exposed to price competition.
• Hydroxyethyl cellulose supports ocular residence time but increases viscosity-related manufacturing demands.
• The Orange Book and current patent databases must be checked for the specific reference product, formulation and jurisdiction.
• Dorzolamide/timolol combination products offer adherence benefits but face a more crowded competitive field.
• Biosimilar risk is not applicable; generic ANDA competition is the relevant pathway.
• The most attractive platform opportunity is a validated preservative-free ophthalmic container that can be reused across multiple glaucoma medicines.

Frequently Asked Questions

Can dorzolamide hydrochloride be formulated without benzalkonium chloride?

Yes. A preservative-free product can use unit-dose packaging or a validated multidose container that prevents microbial contamination. The formulation must demonstrate sterility, container closure integrity and in-use microbiological protection.

Is hydroxyethyl cellulose essential in dorzolamide eye drops?

No. It is a common viscosity modifier, but alternatives such as hypromellose, povidone, polyvinyl alcohol or hyaluronic-acid derivatives may be evaluated. The substitute must preserve product performance and regulatory comparability.

Does a preservative-free dorzolamide product require new clinical trials?

Not necessarily. The requirement depends on the formulation and regulatory pathway. A product that differs materially in excipients, device, dosing performance or labeling may require additional clinical or bridging evidence.

Is dorzolamide hydrochloride suitable for a 505(b)(2) product?

Potentially. A 505(b)(2) pathway may be relevant for a product with a novel delivery system, preservative-free presentation or other meaningful change that cannot rely entirely on an ANDA pathway.

What is the main intellectual-property risk for a new dorzolamide product?

For a conventional generic, the main risk is limited because core molecule and basic formulation protection are historical. For differentiated products, the principal risks are device patents, preservative-free multidose systems, formulation-range claims and combination-product patents.

References

1. Merck Sharp & Dohme LLC. (2023). Trusopt ophthalmic solution prescribing information. U.S. Food and Drug Administration/DailyMed.

2. Merck Sharp & Dohme LLC. (2023). Cosopt ophthalmic solution prescribing information. U.S. Food and Drug Administration/DailyMed.

3. Baudouin, C., Labbe, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2017). 180-day exclusivity: Frequently asked questions. FDA.